Skip to content

Effect of combination of ivabradine and beta-blockers on ventricular rate and exercise tolerance in patients with persistent/permanent atrial fibrillation (CIBER)

Effect of combination of ivabradine and beta-blockers on ventricular rate and exercise tolerance in patients with persistent/permanent atrial fibrillation (CIBER)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026417
Enrollment
Unknown
Registered
2019-10-09
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

A:ivabradine and ß-blockers or ß-blocker
B:ß-blockers or ivabradine and ß-blockers

Sponsors

The Second Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old 2. Resting heart rate (electrocardiography examination 1 week before enrollment) > 110 beats / min. 3. Has not received cardioversion or catheter ablation in the past.

Exclusion criteria

Exclusion criteria: 1. Contraindications to ivabradine and ß-blockers; 2. Pre-excitation syndrome in previous diagnosis; 3. Valvular heart disease; 4. Acute pericarditis, acute myocarditis or constrictive pericarditis; 5. Restrictive hypertrophic cardiomyopathy; 6. Hyperthyroidism; 7. Incomplete severe renal function (estimated glomerular filtration rate 200 mmol/l); 8. Treatment-resistant cardiogenic shock (systolic blood pressure 30 min); 9. Persistently high blood pressure (systolic blood pressure > 180 mmHg or diastolic blood pressure >110 mmHg); 10. Chronic obstructive pulmonary disease, infection, sepsis or other inflammatory diseases; 11. Hospitalization in the past 3 months; 12. History of malignant tumors; 13. Pregnant and/or lactating female; 14. Life expectancy < 1 year; 15. Participating in other clinical trials; 16. Researchers believe patients are not suitable for clinical trials for other reasons.

Design outcomes

Primary

MeasureTime frame
ventricular rate;six minutewalking test;serious adverse events;

Secondary

MeasureTime frame
mEHRA score;LVEF;LAD;AF-QoL score;EuroQol EQ-5D score;

Countries

China

Contacts

Public ContactGao Dengfeng

The Second Affiliated Hospital of Xi'an Jiaotong University

gaomedic@163.com+86 15091544672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026